Topline data announced for phase II COMPARE study evaluating SEL-212 (pegadricase co-administered with ImmTOR immune tolerance platform) for treatment of chronic refractory gout

Study (n=170) reported numerically higher response rate on primary endpoint (serum uric acid <6 mg/dL for ≥80% of time during months 3 and 6 combined) for infusion of SEL-212 once monthly vs. pegloticase twice monthly, but this was not statistically significant (53% vs 46%).

SPS commentary:

SEL-212 consists of pegadricase, a pegylated uricase, co-administered with ImmTOR, designed to mitigate the formation of anti-drug antibodies and thus sustain control of serum uric acid levels.

Biospace Inc.